Abstract 626P
Background
Circulating tumor DNA (ctDNA) analysis with comprehensive panels is now integral to cancer genomic profiling, advancing precision medicine in clinical practice. Yet, the practicality of treatment post ctDNA testing remains uncertain. This study aims to estimate treatment application post ctDNA analysis and its clinical utility.
Methods
Over a 7-month period, from January to July 2023, we retrospectively evaluated 102 patients with solid tumors who underwent ctDNA using the next generation sequencing method at a university-affiliated tertiary care hospital in Korea. To determine the percentage of genome-driven targeted therapy applied subsequent to ctDNA test result, we employed previously reported FDA-approved companion diagnostic biomarkers and their corresponding drug lists. Cases in which FDA-approved targeted therapy was prescribed or cases in which drugs were changed due to drug resistance after ctDNA testing were assessed.
Results
Out of 102 cases evaluated, 81 cases (79.4%) displayed ctDNA sequencing results featuring actionable variants classified as Tier 1 or Tier II. Among the 73 FDA-approved drugs, 12 were administered at our hospital between January 1, 2023, and July 31, 2023. According to ctDNA results, 21 individuals (20.6% of the total cases) were either prescribed FDA-approved drugs or underwent drug changes. Among them, 15 patients (14.7%) were prescribed FDA-approved drugs, while 6 patients (5.9%) experienced alterations in their medication regimens. Of the 21 patients undergoing targeted therapy based on ctDNA test results, colorectal cancer (12/21, 57.1%) was the most prevalent, followed by NSCLC (4/21, 19.0%). Consistent with these cancer types, the most frequently administered drugs were pembrolizumab (8/21, 38.1%) and cetuximab (6/21, 28.6%).
Conclusions
While this study presents findings from an investigation at a tertiary-hospital in Korea, it underscores the significant prevalence of genome-targeted therapy adoption following ctDNA testing for solid tumors. A larger-scale study should be pursued to further validate these observations.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
217P - Conditional reprogramming of urine-derived bladder cancer cells: A model for precision medicine
Presenter: Yu Dong
Session: Poster Display
Resources:
Abstract
218P - Clinical effectiveness of tislelizumab combined with gemcitabine/cisplatin (GC) versus GC as adjuvant therapy in high-risk muscle-invasive urothelial carcinoma (MIUC): A real-world study
Presenter: xingliang Tan
Session: Poster Display
Resources:
Abstract
219P - Clinical effectiveness of tislelizumab plus TKI as first-line therapy in patients with metastatic renal cell carcinoma (mRCC): A real-world study
Presenter: Pei Dong
Session: Poster Display
Resources:
Abstract
220P - Heterogeneity in tertiary lymphoid structures predicts distinct prognosis and immune microenvironment characterizations of clear cell renal cell carcinoma
Presenter: Wenhao Xu
Session: Poster Display
Resources:
Abstract
221P - Genetic polymorphism of genes encoding cytokines interleukin1 1-alpha and TNF-alpha in non-muscle invasive bladder cancer
Presenter: Anil Kumar
Session: Poster Display
Resources:
Abstract
222P - The association between response to enfortumab vedotin and peripheral neuropathy: A multicenter retrospective study in Japan
Presenter: Nozomi Hayakawa
Session: Poster Display
Resources:
Abstract
223P - Patient and healthcare practitioner preferences for treatments in advanced renal cell carcinoma
Presenter: Niara Oliveira
Session: Poster Display
Resources:
Abstract
224P - WUTSUP-01: Phase II trial of neoadjuvant toripalimab and chemotherapy in locally advanced upper tract urothelial carcinoma
Presenter: Yige Bao
Session: Poster Display
Resources:
Abstract
225P - A novel multianalyte signature for stratifying Indian non-muscle invasive bladder cancer: A single center observational study
Presenter: Hari P S
Session: Poster Display
Resources:
Abstract
226P - Prognosis stratification of immunotherapy by a mutational signature in urothelial carcinoma
Presenter: Xuebing Han
Session: Poster Display
Resources:
Abstract